The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...

The companies will focus on advancing AXV-101, with which they hope to treat retinal dystrophy by targeting mutations in the BBS1 gene.

Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...

MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for ...

Viralgen and Axovia Therapeutics are joining forces to advance the development and manufacture of an AAV9-based investigational gene therapy aimed at treating retinal dystrophy in patients with Bardet ...

Inherited retinal diseases (IRDs) are a group of monogenic disorders caused by mutations in more than 280 genes, and are characterized by progressive degeneration of photoreceptor cells in the retina.

A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

A synthetic molecule created in Italy has proven capable to reawakening retinal neurons to stave off degenerative illnesses ...

Inherited eye disorders such as retinitis pigmentosa (RP) leave millions grappling with progressive vision loss. At the heart ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness.